Keywords: Intellipharmaceutics, Par Phara, Focal XR, Novartis, ADHA, Generic formulation

Intellipharmaceutics and Par Pharma expand Focalin accord

Article | 19 August 2011

Print This

Canada’s Intellipharmaceutics International (TSX:I) and US generic drugmaker Par Pharmaceuticals (NYSE: PRX) have added the development and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in